| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 87751 |
诱导基因的定点突变,应用领域 |
213 |
axc |
2024-12-12 |
| 87752 |
基因定点突变技术的实验方案,CRISPR/Cas9技术 |
361 |
axc |
2024-12-12 |
| 87753 |
绿色荧光蛋白GFP基因定点突变的构建 |
525 |
axc |
2024-12-12 |
| 87754 |
PCR技术-基因定点突变 |
552 |
axc |
2024-12-12 |
| 87755 |
设计诱导基因定点突变引物的基本步骤和原则 |
1206 |
axc |
2024-12-12 |
| 87756 |
PCR介导的定点突变,基因定点突变技术 |
901 |
axc |
2024-12-12 |
| 87757 |
基因定点突变概念和应用 |
363 |
axc |
2024-12-12 |
| 87758 |
基因定点突变原理,详情介绍 |
532 |
axc |
2024-12-12 |
| 87759 |
基因点突变细胞株技术流程-CRISPR/Cas9技术 |
299 |
axc |
2024-12-12 |
| 87760 |
定点突变的目的及原理 |
412 |
axc |
2024-12-12 |
| 87761 |
基因定点突变技术 |
312 |
axc |
2024-12-12 |
| 87762 |
DOTA-JR-11,1039726-31-2,白色粉末状螯合剂 |
249 |
h |
2024-12-11 |
| 87763 |
DOTA-(Tyr3)-octreotate,204318-14-9,类似奥曲肽的多肽 |
215 |
h |
2024-12-11 |
| 87764 |
Edotreotide(DOTATOC),生长抑素类似物 |
252 |
h |
2024-12-11 |
| 87765 |
p-SCN-Bn-DOTA,127985-74-4,可用于标记多肽 |
207 |
h |
2024-12-11 |
| 87766 |
PAMAM-PEG-DOTA-Gd,聚酰胺-胺聚乙二醇DOTA钆 |
175 |
h |
2024-12-11 |
| 87767 |
螯合剂多肽,cyclo(RGDFK(DOTA)) |
202 |
h |
2024-12-11 |
| 87768 |
质粒构建的原理及方法 |
1089 |
axc |
2024-12-11 |
| 87769 |
什么是基因过表达(gene overexpression) |
2082 |
axc |
2024-12-11 |
| 87770 |
m-PEG6-(CH2)6-phosphonic acid,cas:2028284-71-9 |
190 |
zcy |
2024-12-11 |
| 87771 |
1201415-84-0,1180007-00-4,DOTA-Lys-Cys-COOH |
166 |
h |
2024-12-11 |
| 87772 |
CRISPR/Cas9系统基因敲除个别外显子(操作步骤) |
897 |
axc |
2024-12-11 |
| 87773 |
大环螯合物DOTA,DOTA-RGD |
163 |
h |
2024-12-11 |
| 87774 |
BocNH-O-(CH₂)₅-COOH BOC 保护基-氨基-五碳链-羧酸 |
246 |
zcy |
2024-12-11 |
| 87775 |
基因敲除方法,基因敲除小鼠定制服务 |
291 |
axc |
2024-12-11 |
| 87776 |
"Maleimide-(CH2)5-COONHS cas:55750-63-5 6-(马来酰亚胺基)己酸琥珀酰亚胺酯" |
190 |
zcy |
2024-12-11 |
| 87777 |
质粒构建的原理、步骤|质粒构建定制服务 |
673 |
axc |
2024-12-11 |
| 87778 |
DOTA-「Tyr3」-Octreotide,Edotreotide,奥曲肽的多肽 |
231 |
h |
2024-12-11 |
| 87779 |
Mal-PEG-CH2CO2H(马来酰亚胺) |
207 |
WYQ |
2024-12-11 |
| 87780 |
Stearic acid-PEG-CH2CO2H |
192 |
WYQ |
2024-12-11 |
| 87781 |
Dotatate,DOTA-奥曲肽 |
208 |
h |
2024-12-11 |
| 87782 |
螯合剂多肽DOTA-cyclo(RGDfK) |
170 |
h |
2024-12-11 |
| 87783 |
Biotin-PEG-CH2CO2H(生物素)(聚乙二醇)(甲基羧酸) |
240 |
WYQ |
2024-12-11 |
| 87784 |
Pomalidomide-PEG4-CH2COOH (CAS: 2097938-44-6) |
160 |
WYQ |
2024-12-11 |
| 87785 |
Pomalidomide-PEG2-CH2COOH (CAS: 2143097-05-4) |
164 |
WYQ |
2024-12-11 |
| 87786 |
Hydroxy-PEG1-CH2-Boc |
177 |
kx |
2024-12-11 |
| 87787 |
Thalidomide-O-PEG2-CH2-Ald (CAS: 2286368-58-7) |
226 |
WYQ |
2024-12-11 |
| 87788 |
双功能螯合剂DOTA-多肽;DOTA-cRGD 大环螯合剂修饰靶向环肽 |
178 |
h |
2024-12-11 |
| 87789 |
DSPE-PEG-CH2COOH(CAS: 474922-20-8) |
254 |
WYQ |
2024-12-11 |
| 87790 |
质粒构建的过程,制备方法 |
535 |
axc |
2024-12-11 |
| 87791 |
Tos-PEG1-CH2-Boc的应用和用途 |
275 |
kx |
2024-12-11 |
| 87792 |
204318-14-9,DOTA-(Tyr3)-octreotate,依多曲肽 |
141 |
h |
2024-12-11 |
| 87793 |
"Maleimide-(CH2)2-COOH cas:7423-55-4 3-马来酰亚胺基丙酸" |
272 |
zcy |
2024-12-11 |
| 87794 |
Propargyl-PEG3-CH2CO2H |
215 |
WYQ |
2024-12-11 |
| 87795 |
DOTA多肽分子探针,619300-53-7 |
225 |
h |
2024-12-11 |